Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
14 Oktober 2021 - 10:06PM
Topline Results from Tofersen Phase 3 Study and its Open Label
Extension in SOD1-ALS to be Presented at the American Neurological
Association Annual Meeting
Biogen Inc. (Nasdaq: BIIB) today announced topline results from its
pivotal Phase 3 VALOR study of tofersen (BIIB067), an
investigational antisense oligonucleotide (ASO) drug being
evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic
lateral sclerosis (ALS), will be presented at the upcoming American
Neurological Association (ANA) 2021 virtual meeting, October 17-19,
2021.
ANA Presentation Details:Sunday, October 17,
2021, 4:20 p.m. ET – Results from the Phase 3 VALOR study and its
open-label extension: evaluating the clinical efficacy and safety
of tofersen in adults with ALS and confirmed SOD1 mutation,
presented by Timothy Miller, M.D., Ph.D., principal investigator of
VALOR and ALS Center Director at Washington University School of
Medicine, St. Louis.
To access the presentation, please go to the Investors section
of Biogen’s website at investors.biogen.com. Following the event,
an archived version will be available on the website.
About TofersenTofersen is an antisense asset
being evaluated for the potential treatment of SOD1-ALS. Tofersen
binds to SOD1 mRNA, allowing for its degradation by RNase-H in an
effort to reduce synthesis of SOD1 protein production. Biogen
licensed tofersen from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS)
under a collaborative development and license agreement.
About BiogenAt Biogen, our mission is clear: we
are pioneers in neuroscience. Biogen discovers, develops and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners
Walter Gilbert and Phillip Sharp. Today Biogen has the leading
portfolio of medicines to treat multiple sclerosis, has introduced
the first approved treatment for spinal muscular atrophy,
commercializes biosimilars of advanced biologics and is focused on
advancing research programs in multiple sclerosis and
neuroimmunology, Alzheimer’s disease and dementia, neuromuscular
disorders, movement disorders, ophthalmology, immunology,
neurocognitive disorders, acute neurology and pain.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter,
LinkedIn, Facebook, YouTube.
MEDIA CONTACT:Ashleigh Koss+ 1
908 205 2572public.affairs@biogen.com |
INVESTOR CONTACT:Mike Hencke+1
781 464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Biogen (TG:IDP)
Historical Stock Chart
Von Mär 2023 bis Mär 2024